Researchers Exploring Methods To Combat Drug-resistant Cancers

Activating proteins like Caspase-3 (CASP3) that promote cell death is the main factor behind many cancer therapies. Several forms of cancer develop resistance to these drugs by down regulating CASP3 through an unknown mechanism. In the absence of CASP3, tumor cells produce another cell death promoting protein CASP7, but it is rendered inactive by the X-linked inhibitor of apoptosis protein (XIAP).

In this issue of the Journal of Clinical Investigation, Po-Huang Liang and colleagues at Academia Sinica identify a compound (I-Lys) that disrupts the interaction between CASP7 and XIAP. Release of CASP7 from this complex in drug resistant cancer cells activated cell death and reduced malignancies. Furthermore, no adverse side effects were observed in non-tumor cells treated with the drug. In the accompanying commentary, Gregory Gores from the Mayo Clinic explains that these results are promising for combatting drug resistant cancers, but more work needs to be done to establish if I-Lys will be safe and beneficial for human use.

No Increased Risk of Certain Cancers from Electromagnetic Fields Among Energy Workers
Electromagnetic fields do not pose a health hazard to workers in the electrical energy supply industry, suggests a large study of 28,000 people

Source-Eurekalert

Death Risk Higher in Obese Women with Colon Cancer
In women with colon cancer that has advanced beyond the early stage, obesity is associated with a poorer long-term outcome, according to a recent

Quality of life after cancer
According to American researchers many cancer survivors report a good quality of life, despite facing physical and psychological struggle. But

Anti-Cancer Drug Restores Normal Cell Growth
An experimental anti-cancer drug has shown effectiveness in treating a resistant type of lymphoma, according to a new report. Researchers say the